Antihypertensive Effect of Fermented Milk Products under the Microscope

Potential health benefits of functional foods based on new lactic acid bacteria offer opportunities for food developers, report investigators in the Journal of Dairy Science®

Philadelphia, PA, May 23, 2016

Over the past decade, interest has been rising in fermented dairy foods that promote health and could potentially prevent diseases such as hypertension (high blood pressure). Functional dairy products that lower blood pressure and heart rate may offer consumers an effective alternative to antihypertensive drugs if their effectiveness can be demonstrated. Investigators reporting in the Journal of Dairy Science® review the scientific basis of reported claims and identify opportunities for developing products based on new lactic acid bacteria.

Hypertension affects more than one billion people throughout the world, according to the World Health Organization. It is an important risk factor for developing other cardiovascular diseases, stroke, renal failure, cerebrovascular accidents, and many other medical complications. Although hypertension can be treated with drugs, these often involve significant side effects. Scientists are therefore seeking out food substances that can help reduce or prevent hypertension.

“Fermented milk has been promoted as a nonpharmacological treatment for hypertension, mainly because of the lack of undesirable side effects, but as yet, there is insufficient evidence to support this according to the European Food Safety Authority (EFSA),” explained lead investigator Belinda Vallejo-Córdoba, PhD, of the Center for Food Research and Development, Sonora, Mexico. “The most studied bioactive peptides derived from dairy proteins are antihypertensive peptides; however, existing studies need to be evaluated before a health claim may be associated with products. With this in mind we have carefully reviewed in vitro and in vivo and clinical studies of fermented milk containing antihypertensive peptides.”

The team of investigators established that the most common strategy to select fermented milks with antihypertensive potential was to identify angiotensin-converting-enzyme (ACE) inhibitory peptides by in vitrostudies. However, they observed that some strains inhibiting ACE activity in vitro did not reduce blood pressure in rats. They evaluated 13 studies with spontaneously hypertensive rats and seven randomized controlled clinical trials in which an antihypertensive effect was demonstrated. Most were based on Lactobacillus helveticus.

Scientifically proven health claims and acquisition of exclusivity rights of using novel food ingredients in functional food products has been observed as a critical factor in ultimate success of these food products in the market. The investigators note that several fermented milk products already on the market attribute their antihypertensive effect to the bioactive peptides present in the fermented milk and draw attention to the fact that some of these commercial products possess intellectual property rights. However, they point out that these products may also contain minerals such as potassium and calcium, which may have a positive effect on blood pressure.

“Although much research related to antihypertensive peptides has already been done, there is a great need for exploration of new lactic acid bacteria that possess the ability to generate this bioactivity as well as good technological properties for the production of fermented dairy products. As commercial fermented milks with antihypertensive effects are scarce and most of the current products are based on Lactobacillus helveticus, there is a great opportunity here,” commented Dr. Vallejo-Córdoba.

The authors recommend future studies to include in vitro lactic acid bacteria screening for ACE-inhibitory effects, in vivo studies with spontaneously hypertensive rats, and clinical trials to test the efficacy of the fermented milk product. “It is also important to develop the regulatory legislation that allows the introduction of health claims for functional dairy foods, especially in countries where this subject is underdeveloped,” Dr. Vallejo-Córdoba concluded.


Notes for editors
“Invited review: Fermented milk as antihypertensive functional food,” by L. M. Beltrán-Barrientos, A. Hernández-Mendoza, M. J. Torres-Llanez, A. F. González-Córdova, and B. Vallejo-Córdoba (doi: 10.3168/jds.2015-10054), Journal of Dairy Science, Volume 99, Issue 6 (June 2016), published by Elsevier. The article is openly available at

Full text of the article is available to credentialed journalists upon request; contact Eileen Leahy at +1 732 238 3628 or to obtain copies or go to To schedule an interview with the authors, please contact Belinda Vallejo-Cordoba at

About Journal of Dairy Science®
Journal of Dairy Science (JDS), official journal of the American Dairy Science Association, is co-published by Elsevier and FASS Inc. for the American Dairy Science Association. It is the leading general dairy research journal in the world. JDS readers represent education, industry, and government agencies in more than 70 countries with interests in biochemistry, breeding, economics, engineering, environment, food science, genetics, microbiology, nutrition, pathology, physiology, processing, public health, quality assurance, and sanitation. JDS has a 5-year Impact Factor of 3.071 according to the 2014 Journal Citation Reports®, published by Thomson Reuters.

About the American Dairy Science Association (ADSA)
The American Dairy Science Association (ADSA) is an international organization of educators, scientists, and industry representatives who are committed to advancing the dairy industry and keenly aware of the vital role the dairy sciences play in fulfilling the economic, nutritive, and health requirements of the world's population. It provides leadership in scientific and technical support to sustain and grow the global dairy industry through generation, dissemination, and exchange of information and services. Together, ADSA members have discovered new methods and technologies August that have revolutionized the dairy industry.

About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

Media contacts
Eileen Leahy
+1 732 238 3628

Ken Olson, PhD, PAS
American Dairy Science Association®
+1 630 237 4961